NOW… You can Dance if You Want to

June 25, 2018 1:45pm

Eric W. Dittmann
Partner
Paul Hastings LLP (New York, NY)

Chuck Klein
Co-chair, Intellectual Property Practice
Winston & Strawn LLP (Washington, DC)

Christopher Loh
Partner
Fitzpatrick, Cella, Harper & Scinto (New York, NY)

Nicholas Mitrokostas
Partner, IP Litigation
Goodwin Procter LLP (Boston, MA)

Rachel Moodie
Vice President Intellectual Property, Biosimilars
Fresenius Kabi SwissBioSim GmbH (Aubonne, CH)

MODERATOR:

Laurie Hill
Vice President of Intellectual Property
Genentech (South San Francisco, CA)

Now that one year has passed since Sandoz v. Amgen, the biologics industry still finds itself in a state of uncertainty with respect to the dance, and choosing the most successful “dance moves.” This interactive panel will include an in-depth analysis of several mock fact patterns where the parties will address the most pressing challenges still keeping the market up at night, including:  
  • Benefits and risks of taking part in the patent dance
  • What is the minimum requirement necessary to constitute compliance
  • Strategic use of notice of commercial marketing
  • Pros and Cons for biosimilar makers to provide manufacturing information
  • Settlements and potential antitrust concerns